The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies
Open accessAbstract
Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease that affects children and adults. Until recently, the only Food and Drug Administration-approved systemic treatment option for patients with moderate-to-severe AD was systemic steroids, which are not recommended by current guidelines and are commonly associated with disease rebound. Instead, clinicians choose from several off-label immunosuppressants, which can have serious adverse effects. A significant number of these patients go untreated. Research on the immunopathogenesis of AD has paved the way for new, targeted, systemic therapies for moderate-to-severe AD. In early 2017, the Food and Drug Administration approved dupilumab for adults with moderate-to-severe AD whose disease is not adequately controlled with topical therapies. Although the national guidelines can be very helpful to clinicians, the process for updating them does not allow for timely incorporation of novel therapies. A steering committee of AD experts, including dermatologists, allergists, and a patient advocacy group representative, developed recommendations on the basis of a literature review and expert opinion to help clinicians understand how new therapies fit into the current treatment paradigm and to provide practical recommendations for assessing AD severity, treatment response, and treatment failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationWILLIAMS, H. C., JBURNEY, P. G., HAY, R. J., ARCHER, C. B., SHIPLEY, M. J., AHUNTER, J. J., BINGHAM, E. A., FINLAY, A. Y., PEMBROKE, A. C., CGRAHAM-BROWN, R. A., et al. (1994) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1994.tb08530.x · Cited by 1,271
Allergen immunotherapy: A practice parameter third update
Cox, L., Nelson, H., Lockey, R., Calabria, C., Chacko, T., Finegold, I., Nelson, M., Weber, R., Bernstein, D. I., Blessing-Moore, J., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.09.034 · Cited by 1,256
Global Skin Disease Morbidity and Mortality: An Update From the Global Burden of Disease Study 2013
Karimkhani, C., Dellavalle, R. P., Coffeng, L. E., Flohr, C., Hay, R. J., Langan, S. M., Nsoesie, E. O., Ferrari, A. J., Erskine, H. E., Silverberg, J. I., et al. (2017) · JAMA Dermatology · doi:10.1001/jamadermatol.2016.5538 · Cited by 742
Self-citationAnti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606490 · Cited by 592
WILLIAMS, H. C., JBURNEY, P. G., STRACHAN, D., HAY, R. J., & Party, A. D. D. C. W. (1994) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1994.tb08531.x · Cited by 273
DOCK8 deficiency: Insights into pathophysiology, clinical features and management
Biggs, C. M., Keles, S., & Chatila, T. A. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.06.003 · Cited by 178
Thymus and activation‐regulated chemokine as a clinical biomarker in atopic dermatitis
Kataoka, Y. (2014) · The Journal of Dermatology · doi:10.1111/1346-8138.12440 · Cited by 150
Cited by
Guttman-Yassky, E., Brunner, P. M., Neumann, A. U., Khattri, S., Pavel, A. B., Malik, K., Singer, G. K., Baum, D., Gilleaudeau, P., Sullivan-Whalen, M., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.016 · Cited by 343
Self-citationTorres, T., Ferreira, E. O., Gonçalo, M., Mendes-Bastos, P., Selores, M., & Filipe, P. (2019) · Acta Médica Portuguesa · doi:10.20344/amp.11963 · Cited by 298
Deleuran, M., Thaçi, D., Beck, L. A., de Bruin-Weller, M., Blauvelt, A., Forman, S., Bissonnette, R., Reich, K., Soong, W., Hussain, I., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.07.074 · Cited by 255
Self-citationGuttman-Yassky, E., Pavel, A. B., Zhou, L., Estrada, Y. D., Zhang, N., Xu, H., Peng, X., Wen, H.-C., Govas, P., Gudi, G., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.11.053 · Cited by 220
Self-citationAriëns, L., Nimwegen, K., Shams, M., Bruin, D., Schaft, J., Os-Medendorp, H., & Bruin-Weller, M. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3212 · Cited by 79
Metadata
- Authors
- Boguniewicz, M., Alexis, A. F., Beck, L. A., Block, J., Eichenfield, L. F., Fonacier, L., Guttman-Yassky, E., Paller, A. S., Pariser, D., Silverberg, J. I., & Lebwohl, M.
- Venue
- The Journal of Allergy and Clinical Immunology: In Practice
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 5
- Issue
- 6
- Pages
- 1519-1531
- ISSN
- 2213-2198 (ISSN-L)
- OpenAlex
- W2760088364
- Cited by
- 191
- References
- 8
- FWCI
- 16.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies. https://app.cochat.ai/papers/10.1016/j.jaip.2017.08.005
- The paper
- Boguniewicz, M., Alexis, A. F., Beck, L. A., Block, J., Eichenfield, L. F., Fonacier, L., Guttman-Yassky, E., Paller, A. S., Pariser, D., Silverberg, J. I., & Lebwohl, M. (2017). Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2017.08.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
